As a result, KIF22-targeting inhibitors may be used as adjuncts to MEK-ERK inhibitors to increase drug sensitivity and reduce biotoxicity, slow pancreatic cancer progression, reduce postoperative recurrence rate, and improve pancreatic cancer patients' survival outcomes. Here, MAP2K7 is linked to familial pancreatic carcinoma.